Biotech

Deal making concept
#Biotech

Biotechnology companies reach agreement to advance vectorised antibodies

Biotechnology companies VectorY Therapeutics and Shape Therapeutics have reached an exclusive license agreement to develop vectorised antibodies for neurodegenerative diseases.  The agreement grants VectorY an exclusive option to evaluate Shape’s deep-brain penetrating adeno-associated virus (AAV) capsid, SHP-DB1, for vectorised antibody payloads against three therapeutic targets. Shape will grant access to its proprietary capsid… Read More

#Business & Investment #News

#Biotech #Dermatology #Drug discovery

Talking leadership with Leo Pharma

DDW speaks to Leanne Walsh, General Manager & VP at LEO Pharma UK & Ireland about her career in the pharmaceutical industry. DDW: Can you tell us about your current role at LEO Pharma and how it reflects your leadership approach?  LW: At LEO Pharma, I lead the UK and… Read More

#Exclusive Content

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #Orphan drugs

EMA positive towards unique Huntington’s drug

The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion for granting orphan drug designation (ODD) to the drug SOM3355 for the treatment of Huntington’s disease.  The decision made by the EMA’s Committee for Orphan Medical Product (COMP) recognises an ongoing… Read More

#News

European Commission President Ursula von der Leyen
#Biotech #Biotech hubs #Europe #European Commission #European Union #Market reporting

Can Europe take the lead on biotech?

With uncertainty across the global financial markets and research community, is it Europe’s time to take the lead on biotech? Diana Turner reports.  While biotech has so far been dominated by the US, since the inauguration of Donald Trump in January 2025, there has been considerable uncertainty, with significant cuts… Read More

#Exclusive Content #Market Reports #Trends & Analysis

AAV virus
#AAV #Biotech #Collaboration #Oncology

Partners advance virus-like particle platform for liver cancer

Hovione and Firstgene Life Sciences have announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by Firstgene.  Under the terms of the collaboration, Hovione will grant Firstgene an exclusive license to its proprietary novel… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Biotech #DDW Turning Science into Business Summit #Drug discovery

Register now: Learn to navigate AI-driven drug discovery

Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register now for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. Taking place on 30 April,… Read More

#News

Machine learning concept
#AI / data analytics / healthtech / informatics #Biotech #DDW Turning Science into Business Summit #Drug discovery

Webinar: Navigating AI-driven drug discovery

Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register now for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. Taking place on 30 April,… Read More

#News

AI and genomics
#AI / data analytics / healthtech / informatics #Biotech #DDW Turning Science into Business Summit #Drug discovery

Webinar: Areas of opportunity for AI and ML in drug discovery

Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register now for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. Taking place on 30 April,… Read More

#News

#AI / data analytics / healthtech / informatics #Biotech #DDW Turning Science into Business Summit #Drug discovery

Register now for DDW’s AI & ML summit

Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register now for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. Taking place on 30 April,… Read More

#News

Drug discovery
#Artificial intelligence (AI) #Biotech #Cell analysis #Drug discovery #Flow Cytometry

The future direction and applications of flow cytometry

Miguel Tam, Director of Strategic Marketing at Revvity’s BioLegend, explores the future directions and applications of flow cytometry in drug discovery, highlighting the opportunities it presents and the challenges that lie ahead  Flow cytometry has long been a cornerstone in biomedical research and clinical diagnostics, offering unparalleled capabilities to analyse… Read More

#Exclusive Content

#Biotech #Business #China #Drug discovery #Funding

How has the biotech international market planning evolved

Sam Tomlinson, Vice President of Global Drug Safety at Arriello unpacks North America/EU research which compares today’s commercialisation strategies with those of five years ago.   As biotechs around the world look to new territories including emerging markets for their next returns, many are encountering unexpected hurdles. Too often, there is a… Read More

#Exclusive Content

AI and robotics
#AI / data analytics / healthtech / informatics #Automation #Biotech #Drug development #Drug discovery #Regulatory

Unsustainable regulatory workloads leave no choice about AI adoption 

To determine where pharma/biopharma regulatory functions see the greatest potential for AI technology, ArisGlobal commissioned an exclusive survey1 of senior regulatory professionals in US pharma and biopharma organisations. The research was conducted in early September 2024. Discussing the findings, Renato Rjavec from ArisGlobal notes that, although plans to invest in regulatory AI… Read More

#Exclusive Content #Regulatory

#Biotech #Digitalisation #Drug development #Regulatory

Why late-stage pharma R&D processes need a rethink 

Across pharma regulatory affairs, quality and pharmacovigilance/drug safety functions, process rigour is wedded tightly to SOPs. But these snapshot definitions of processes do not, of themselves, foster efficiency. In many cases, there has been a loss of sight of the deliverables. Here, Tobias Hitziger, Management Consultant at MAIN5 considers what… Read More

#Exclusive Content #Regulatory

Woman tests blood glucose level
#AdipoPharma #Biotech #Clinical trials #France #Funding #Type 2 diabetes

Investments pave way for type 2 diabetes breakthrough 

French biotech AdipoPharma is developing a novel and promising type 2 diabetes drug, for which it has successfully secured the funding needed to begin Phase I clinical trials. The company expects to begin clinical trials in the US in mid-2025.     This funding will enable AdipoPharma to accelerate… Read More

#News

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Drug discovery

Rethinking the pharma R&D lifecycle with AI in mind

Ashu Singhal and Sajith Wickramasekara, co-founders of Benchling, explore how AI's true promise for the pharmaceutical industry can only be realised if the entire pharmaceutical R&D lifecycle is supported. Drug discovery has quickly become a trendy place to apply AI. Billions of dollars are being invested in AI-driven techbios and… Read More

#Exclusive Content